超重肥胖青少年认知功能的改变及其与血清FGF21水平的关系

doi:10.3969/j.issn.1674-8115.2024.01.010

上海交通大学学报（医学版） ›› 2024, Vol. 44 ›› Issue (1): 87-97.doi: 10.3969/j.issn.1674-8115.2024.01.010

超重肥胖青少年认知功能的改变及其与血清FGF21水平的关系

韩瑞¹^,²(), 吴倩¹^,²(), 刘丹¹^,², 程棣¹^,², 张盈¹^,², 倪嘉成¹, 康飘¹^,², 陈安然¹^,², 于淑洁¹^,², 方启晨¹, 李华婷¹^,²()

^1.上海交通大学医学院附属第六人民医院内分泌代谢科，上海市糖尿病研究所，上海市糖尿病重点实验室，上海市糖尿病临床医学中心，上海 200233
^2.上海交通大学医学院，上海 200025

收稿日期:2023-05-31 接受日期:2023-12-21 出版日期:2024-01-28 发布日期:2024-02-28
通讯作者: 李华婷 E-mail:Hanrui517@163.com;wuqian2021@sjtu.edu.cn;huarting99@sjtu.edu.cn
作者简介:韩　瑞（1996—），男，硕士生；电子信箱：Hanrui517@163.com
吴　倩（1998—），女，侗族，硕士生；电子信箱：wuqian2021@sjtu.edu.cn第一联系人：（韩　瑞、吴　倩并列第一作者）
基金资助:
国家自然科学基金(82022012);上海交通大学医学院“双百人”项目(20221830);上海市高水平地方高校创新团队(SSMU-ZDCX20212700);上海市内分泌与代谢疾病研究中心(2022ZZ01002)

Alteration of cognitive function in overweight and obese adolescents and its relationship with serum FGF21 levels

HAN Rui¹^,²(), WU Qian¹^,²(), LIU Dan¹^,², CHENG Di¹^,², ZHANG Ying¹^,², NI Jiacheng¹, KANG Piao¹^,², CHEN Anran¹^,², YU Shujie¹^,², FANG Qichen¹, LI Huating¹^,²()

^1.Shanghai Clinical Center for Diabetes, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Diabetes Institute, Department of Endocrinology and Metabolism, Shanghai Sixth People′s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China
^2.Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received:2023-05-31 Accepted:2023-12-21 Online:2024-01-28 Published:2024-02-28
Contact: LI Huating E-mail:Hanrui517@163.com;wuqian2021@sjtu.edu.cn;huarting99@sjtu.edu.cn
Supported by:
National Natural Science Foundation of China(82022012);"Two-hundred Talents" Program of Shanghai Jiao Tong University School of Medicine(20221830);Innovative Research Team of High-level Local Universities in Shanghai(SSMU-ZDCX20212700);Shanghai Research Center for Endocrine and Metabolic Diseases(2022ZZ01002)

摘要/Abstract

摘要：

目的·评估超重、肥胖青少年认知功能的改变，并探索认知功能与成纤维细胞生长因子21（fibroblast growth factor 21，FGF21）的关联。方法·选取上海市某高级中学的175名青少年，根据体质量指数（body mass index，BMI）分为正常体型组（n=50）、超重组（n=50）和肥胖组（n=75）。收集并比较青少年的一般资料、人体测量学资料及实验室检测指标。采用Flanker任务（侧抑制任务）和n-back任务（倒数n项测试范式）行为学试验的正确率（accuracy，ACC）和反应时评估3组青少年的认知功能，通过酶联免疫吸附试验检测其血清FGF21水平。通过偏相关分析、多元线性回归模型评估青少年行为学试验表现与人体测量学资料、实验室检测指标的相关性。结果·与正常体型组相比，肥胖组青少年的收缩压、舒张压及空腹血糖、糖化血红蛋白、三酰甘油水平较高（均P<0.05）。在Flanker任务的一致或不一致性刺激条件下，任意2组青少年的ACC间差异均无统计学意义；与正常体型组、超重组相比，肥胖组青少年的反应时均有延长（均P<0.05）。在n-back任务中，任意2组青少年的ACC间差异均无统计学意义，而肥胖组青少年在1-back和2-back任务中的反应时较正常体型组、超重组更长（均P<0.05）。与正常体型组相比，肥胖组青少年血清FGF21水平较高（P=0.000）。偏相关分析的结果显示，Flanker和n-back任务中青少年的反应时与其BMI、体脂肪量、腰围、腰臀比、FGF21水平等相关（均P<0.05）。多元线性回归分析进一步证实，BMI与青少年认知相关行为学任务中反应时延长相关（均P<0.05），且FGF21水平与2-back任务的ACC（P=0.000）、不一致性刺激的反应时（P=0.048）相关。结论·超重、肥胖青少年存在认知功能障碍，BMI、血清FGF21水平与该类青少年认知功能的改变相关。

关键词: 肥胖青少年, 认知功能, 行为学试验, 成纤维细胞生长因子21

Abstract:

Objective ·To evaluate the changes in cognitive function in overweight and obese adolescents, and explore the association between cognitive function and fibroblast growth factor 21 (FGF21). Methods ·A total of 175 adolescents from a senior high school in Shanghai were divided into normal weight group (n=50), overweight group (n=50) and obese group (n=75) based on their body mass index (BMI). General information, anthropometric data and laboratory testing indicators of the adolescents were collected and compared. The cognitive function of the three groups of adolescents was assessed by using the accuracy (ACC) and reaction time of Flanker task and n-back task. Enzyme-linked immunosorbent assay (ELISA) was used to detect the serum FGF21 level of the three groups of adolescents. Partial correlation analysis and multiple linear regression model were used to evaluate the correlation between cognitive task performance and anthropometric data and laboratory testing indicators. Results ·Compared with the normal weight group, systolic blood pressure, diastolic blood pressure, and the levels of fasting plasma glucose, glycosylated hemoglobin and triacylglycerol in the obese group were higher (all P<0.05). Under congruent or incongruent stimulus conditions in the Flanker task, there was no significant difference in ACC between any two groups; compared with the normal weight and overweight groups, the reaction time of the adolescents in the obese group was prolonged (all P<0.05). In the n-back task, there were no significant differences in ACC between any two groups, while the obese group had longer reaction time in the 1-back and 2-back tasks compared to the normal weight and overweight groups (all P<0.05). Compared with the normal weight group, serum FGF21 levels of the adolescents in the obese group were higher (P=0.000). Partial correlation analysis showed that the reaction time of the adolescents in Flanker and n-back tasks was correlated with their BMI, body fat mass, waist circumference, waist-to-hip ratio and FGF21 level (all P<0.05). Multiple linear regression analysis further confirmed that BMI was associated with prolonged reaction time in cognitive-related behavioral tasks in the adolescents (all P<0.05), and FGF21 level was associated with ACC in the 2-back task (P=0.000) and reaction time in the incongruent stimulus condition (P=0.048). Conclusion ·Overweight and obese adolescents have cognitive impairments, and BMI and serum FGF21 levels are associated with changes in their cognitive function.

Key words: obese adolescent, cognitive function, behavioral experiment, fibroblast growth factor 21 (FGF21)

中图分类号:

R589

韩瑞, 吴倩, 刘丹, 程棣, 张盈, 倪嘉成, 康飘, 陈安然, 于淑洁, 方启晨, 李华婷. 超重肥胖青少年认知功能的改变及其与血清FGF21水平的关系[J]. 上海交通大学学报（医学版）, 2024, 44(1): 87-97.

HAN Rui, WU Qian, LIU Dan, CHENG Di, ZHANG Ying, NI Jiacheng, KANG Piao, CHEN Anran, YU Shujie, FANG Qichen, LI Huating. Alteration of cognitive function in overweight and obese adolescents and its relationship with serum FGF21 levels[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(1): 87-97.

图/表 8

参考文献 28

1	PAN X F, WANG L M, PAN A. Epidemiology and determinants of obesity in China[J]. Lancet Diabetes Endocrinol, 2021, 9(6): 373-392.
2	DE MUTSERT R, SUN Q, WILLETT W C, et al. Overweight in early adulthood, adult weight change, and risk of type 2 diabetes, cardiovascular diseases, and certain cancers in men: a cohort study[J]. Am J Epidemiol, 2014, 179(11): 1353-1365.
3	GUNSTAD J, PAUL R H, COHEN R A, et al. Elevated body mass index is associated with executive dysfunction in otherwise healthy adults[J]. Compr Psychiatry, 2007, 48(1): 57-61.
4	BOZKURT H, ÖZER S, YıLMAZ R, et al. Assessment of neurocognitive functions in children and adolescents with obesity[J]. Appl Neuropsychol Child, 2017, 6(4): 262-268.
5	PAN L Y, LI X X, FENG Y, et al. Psychological assessment of children and adolescents with obesity[J]. J Int Med Res, 2018, 46(1): 89-97.
6	HODEL A S, BRUMBAUGH J E, HUNT R H, et al. Individual differences in ERP measures of executive function in early childhood: relation to low-risk preterm birth and parent-reported behavior[J]. Child Neuropsychol, 2019, 25(7): 914-942.
7	PIRES L, LEITÃO J, GUERRINI C, et al. Event-related brain potentials in the study of inhibition: cognitive control, source localization and age-related modulations[J]. Neuropsychol Rev, 2014, 24(4): 461-490.
8	ETNIER J L, CHANG Y K. The effect of physical activity on executive function: a brief commentary on definitions, measurement issues, and the current state of the literature[J]. J Sport Exerc Psychol, 2009, 31(4): 469-483.
9	RÉVEILLON M, LAZEYRAS F, VAN CALSTER L, et al. Neural functional correlates of the impact of socio-emotional stimuli on performances on a flanker task in children aged 9-11 years[J]. Neuropsychologia, 2020, 145: 106747.
10	YAPLE Z, ARSALIDOU M. N-back working memory task: meta-analysis of normative fMRI studies with children[J]. Child Dev, 2018, 89(6): 2010-2022.
11	PELEGRINA S, LECHUGA M T, GARCÍA-MADRUGA J A, et al. Normative data on the n-back task for children and young adolescents[J]. Front Psychol, 2015, 6: 1544.
12	MÄKELÄ J, TSELYKH T V, MAIORANA F, et al. Fibroblast growth factor-21 enhances mitochondrial functions and increases the activity of PGC-1α in human dopaminergic neurons via Sirtuin-1[J]. SpringerPlus, 2014, 3: 2.
13	KIM K H, LEE M S. FGF21 as a stress hormone: the roles of FGF21 in stress adaptation and the treatment of metabolic diseases[J]. Diabetes Metab J, 2014, 38(4): 245-251.
14	KANG K, XU P F, WANG M X, et al. FGF21 attenuates neurodegeneration through modulating neuroinflammation and oxidant-stress[J]. Biomed Pharmacother, 2020, 129: 110439.
15	中华人民共和国国家卫生健康委员会. 学龄儿童青少年超重与肥胖筛查[EB/OL]. (2018-02-23) [2023-05-31]. http://www.nhc.gov.cn/wjw/pqt/201803/a7962d1ac01647b9837110bfd2d69b26.shtml.
	National Health Commission of People's Republic of China. Overweight and obesity screening in school-age children and adolescents[EB/OL]. (2018-02-23) [2023-05-31]. http://www.nhc.gov.cn/wjw/pqt/201803/a7962d1ac01647b9837110bfd2d69b26.shtml.
16	LI H T, DONG K, FANG Q C, et al. High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: a 3-year prospective study in China[J]. J Hepatol, 2013, 58(3): 557-563.
17	KAMIJO K, PONTIFEX M B, KHAN N A, et al. The negative association of childhood obesity to cognitive control of action monitoring[J]. Cereb Cortex, 2014, 24(3): 654-662.
18	REDDY S D, SYSKO R, MACKEY E R. Mental health, loss of control eating, and cognitive functioning in adolescents undergoing bariatric surgery[J]. Semin Pediatr Surg, 2020, 29(1): 150892.
19	CHAN J S Y, YAN J H, PAYNE V G. The impact of obesity and exercise on cognitive aging[J]. Front Aging Neurosci, 2013, 5: 97.
20	NIEOULLON A, COQUEREL A. Dopamine: a key regulator to adapt action, emotion, motivation and cognition[J]. Curr Opin Neurol, 2003, 16(Suppl 2): S3-S9.
21	SOLAS M, MILAGRO F I, RAMÍREZ M J, et al. Inflammation and gut-brain axis link obesity to cognitive dysfunction: plausible pharmacological interventions[J]. Curr Opin Pharmacol, 2017, 37: 87-92.
22	MINA T, YEW Y W, NG H K, et al. Adiposity impacts cognitive function in Asian populations: an epidemiological and Mendelian Randomization study[J]. Lancet Reg Health West Pac, 2023, 33: 100710.
23	JEON B T, JEONG E A, SHIN H J, et al. Resveratrol attenuates obesity-associated peripheral and central inflammation and improves memory deficit in mice fed a high-fat diet[J]. Diabetes, 2012, 61(6): 1444-1454.
24	DAVIDSON T L, MONNOT A, NEAL A U, et al. The effects of a high-energy diet on hippocampal-dependent discrimination performance and blood-brain barrier integrity differ for diet-induced obese and diet-resistant rats[J]. Physiol Behav, 2012, 107(1): 26-33.
25	BOCARSLY M E, FASOLINO M, KANE G A, et al. Obesity diminishes synaptic markers, alters microglial morphology, and impairs cognitive function[J]. Proc Natl Acad Sci U S A, 2015, 112(51): 15731-15736.
26	XIAO F, SHI X, HUANG P, et al. Dose-response relationship between serum fibroblast growth factor 21 and liver fat content in non-alcoholic fatty liver disease[J]. Diabetes Metab, 2021, 47(6): 101221.
27	FISHER F M, CHUI P C, ANTONELLIS P J, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state[J]. Diabetes, 2010, 59(11): 2781-2789.
28	YE L X, WANG X, CAI C C, et al. FGF21 promotes functional recovery after hypoxic-ischemic brain injury in neonatal rats by activating the PI3K/Akt signaling pathway via FGFR1/β-klotho[J]. Exp Neurol, 2019, 317: 34-50.

Item	Normal weight group (n=50)	Overweight group (n=50)	Obese group (n=75)	P value
General information
Age/year	15.18 ± 0.48	15.52 ± 0.58	15.31 ± 0.52	0.327
Gender (male/female)/n	29/21	30/20	50/25	0.117
BMI/(kg·m^-2)	21.35 ± 2.16	25.26 ± 0.98^*	30.37 ± 2.73^*#	0.000
Body fat mass/kg	12.73 ± 4.90	20.91 ± 4.69^*	29.95 ± 6.62^*#	0.000
Body fat percentage/%	20.93 ± 7.73	28.47 ± 7.21^*	33.55 ± 5.83^*#	0.000
Waist circumference/cm	73.95 ± 7.48	82.87 ± 3.69^*	95.53 ± 9.14^*#	0.000
Hip circumference/cm	94.70 ± 5.77	103.71 ± 3.80^*	110.09 ± 5.38^*#	0.000
Waist-to-hip ratio	0.80 ± 0.04	0.84 ± 0.01^*	0.89 ± 0.03^*#	0.000
SBP/mmHg	115.04 ± 12.27	120.29 ± 11.51	124.39 ± 9.98^*	0.000
DBP/mmHg	63.84 ± 7.42	69.09 ± 8.73^*	70.44 ± 9.27^*	0.000
Laboratory testing indicator
FPG/(mmol·L^-1)	4.62 ± 0.35	4.78 ± 0.30	4.79 ± 0.37^*	0.014
FINS/(mmol·L^-1)	15.03 (11.43, 19.28)	21.67 (17.62, 29.76)^*	29.94 (18.96, 38.32)^*#	0.000
HbA1c/%	5.31 ± 0.21	5.32 ± 0.16	5.42 ± 0.27^*	0.008
Scr/(µmol·L^-1)	65.95 (58.40, 76.85)	66.25 (56.33, 73.83)^*	71.90 (63.50, 79.50)^{* #}	0.052
UA/(µmol·L^-1)	368.86 ± 85.19	397.66 ± 82.31	451.24 ± 102.53^*	0.000
ALT/(U·L^-1)	14.00 (11.00, 17.25)	17.50 (15.00, 27.00)^*	26.00 (20.00, 48.00)^*#	0.000
AST/(U·L^-1)	21.00 (17.75, 24.00)	21.00 (18.00, 26.25)	26.00 (20.00, 32.00)^*	0.000
GGT/(U·L^-1)	16.50 (14.00, 21.00)	19.50 (14.75, 25.00)	23.00 (17.00, 32.00)^*#	0.000
TC/(mmol·L^-1)	4.36 ± 0.78	4.30 ± 0.76^*	4.33 ± 0.74^*#	0.880
TAG/(mmol·L^-1)	0.74 (0.55, 1.04)	0.87 (0.61, 1.29)	0.92 (0.69, 1.37)	0.012
HDL-Ch/(mmol·L^-1)	1.44 ± 0.29	1.26 ± 0.26^*	1.21 ± 0.25^*	0.000
LDL-Ch/(mmol·L^-1)	2.48 ± 0.70	2.56 ± 0.56	2.69 ± 0.69	0.076

Item	Normal weight group (n=50)	Overweight group (n=50)	Obese group (n=75)	P value
General information
Age/year	15.18 ± 0.48	15.52 ± 0.58	15.31 ± 0.52	0.327
Gender (male/female)/n	29/21	30/20	50/25	0.117
BMI/(kg·m^-2)	21.35 ± 2.16	25.26 ± 0.98^*	30.37 ± 2.73^*#	0.000
Body fat mass/kg	12.73 ± 4.90	20.91 ± 4.69^*	29.95 ± 6.62^*#	0.000
Body fat percentage/%	20.93 ± 7.73	28.47 ± 7.21^*	33.55 ± 5.83^*#	0.000
Waist circumference/cm	73.95 ± 7.48	82.87 ± 3.69^*	95.53 ± 9.14^*#	0.000
Hip circumference/cm	94.70 ± 5.77	103.71 ± 3.80^*	110.09 ± 5.38^*#	0.000
Waist-to-hip ratio	0.80 ± 0.04	0.84 ± 0.01^*	0.89 ± 0.03^*#	0.000
SBP/mmHg	115.04 ± 12.27	120.29 ± 11.51	124.39 ± 9.98^*	0.000
DBP/mmHg	63.84 ± 7.42	69.09 ± 8.73^*	70.44 ± 9.27^*	0.000
Laboratory testing indicator
FPG/(mmol·L^-1)	4.62 ± 0.35	4.78 ± 0.30	4.79 ± 0.37^*	0.014
FINS/(mmol·L^-1)	15.03 (11.43, 19.28)	21.67 (17.62, 29.76)^*	29.94 (18.96, 38.32)^*#	0.000
HbA1c/%	5.31 ± 0.21	5.32 ± 0.16	5.42 ± 0.27^*	0.008
Scr/(µmol·L^-1)	65.95 (58.40, 76.85)	66.25 (56.33, 73.83)^*	71.90 (63.50, 79.50)^{* #}	0.052
UA/(µmol·L^-1)	368.86 ± 85.19	397.66 ± 82.31	451.24 ± 102.53^*	0.000
ALT/(U·L^-1)	14.00 (11.00, 17.25)	17.50 (15.00, 27.00)^*	26.00 (20.00, 48.00)^*#	0.000
AST/(U·L^-1)	21.00 (17.75, 24.00)	21.00 (18.00, 26.25)	26.00 (20.00, 32.00)^*	0.000
GGT/(U·L^-1)	16.50 (14.00, 21.00)	19.50 (14.75, 25.00)	23.00 (17.00, 32.00)^*#	0.000
TC/(mmol·L^-1)	4.36 ± 0.78	4.30 ± 0.76^*	4.33 ± 0.74^*#	0.880
TAG/(mmol·L^-1)	0.74 (0.55, 1.04)	0.87 (0.61, 1.29)	0.92 (0.69, 1.37)	0.012
HDL-Ch/(mmol·L^-1)	1.44 ± 0.29	1.26 ± 0.26^*	1.21 ± 0.25^*	0.000
LDL-Ch/(mmol·L^-1)	2.48 ± 0.70	2.56 ± 0.56	2.69 ± 0.69	0.076

Item	Normal weight group (n=50)	Overweight group (n=50)	Obese group (n=75)	P value
Flanker task
ACC
Congruent stimulus	0.97 ± 0.09	0.97 ± 0.04	0.98 ± 0.04	0.442
Incongruent stimulus	0.92 ± 0.09	0.93 ± 0.10	0.92 ± 0.14	0.854
Reaction time/ms
Congruent stimulus	406.12 ± 108.32	431.35 ± 85.17	475.13 ± 84.31	0.000
Incongruent stimulus	465.41 ± 95.59	463.55 ± 59.92	524.01 ± 103.79	0.000
n-back task
ACC
0-back	0.94 ± 0.05	0.93 ± 0.07	0.93 ± 0.08	0.641
1-back	0.84 ± 0.12	0.85 ± 0.08	0.86 ± 0.12	0.404
2-back	0.78 ± 0.13	0.72 ± 0.16	0.78 ± 0.15	0.751
Reaction time/ms
0-back	522.52 ± 103.11	539.48 ± 104.85	564.34 ± 116.74	0.050
1-back	541.76 ± 149.67	587.90 ± 160.04	656.60 ± 168.99	0.000
2-back	570.49 ± 174.48	625.08 ± 199.08	754.24 ± 201.57	0.000

Item	Normal weight group (n=50)	Overweight group (n=50)	Obese group (n=75)	P value
Flanker task
ACC
Congruent stimulus	0.97 ± 0.09	0.97 ± 0.04	0.98 ± 0.04	0.442
Incongruent stimulus	0.92 ± 0.09	0.93 ± 0.10	0.92 ± 0.14	0.854
Reaction time/ms
Congruent stimulus	406.12 ± 108.32	431.35 ± 85.17	475.13 ± 84.31	0.000
Incongruent stimulus	465.41 ± 95.59	463.55 ± 59.92	524.01 ± 103.79	0.000
n-back task
ACC
0-back	0.94 ± 0.05	0.93 ± 0.07	0.93 ± 0.08	0.641
1-back	0.84 ± 0.12	0.85 ± 0.08	0.86 ± 0.12	0.404
2-back	0.78 ± 0.13	0.72 ± 0.16	0.78 ± 0.15	0.751
Reaction time/ms
0-back	522.52 ± 103.11	539.48 ± 104.85	564.34 ± 116.74	0.050
1-back	541.76 ± 149.67	587.90 ± 160.04	656.60 ± 168.99	0.000
2-back	570.49 ± 174.48	625.08 ± 199.08	754.24 ± 201.57	0.000

Item	ACC		Reaction time
Item	Incongruent stimulus	Congruent stimulus	Incongruent stimulus	Congruent stimulus
BMI	-0.004 (0.958)	0.033 (0.678)	0.259 (0.000)	0.337 (0.000)
Body fat mass	0.004 (0.963)	0.014 (0.857)	0.154 (0.045)	0.242 (0.000)
Body fat percentage	-0.013 (0.874)	-0.024 (0.764)	0.061 (0.431)	0.193 (0.011)
Waist-to-hip ratio	0.008 (0.928)	0.054 (0.495)	0.217 (0.004)	0.280 (0.000)
Waist circumference	0.007 (0.930)	-0.018 (0.820)	0.156 (0.042)	0.269 (0.000)
Hip circumference	-0.016 (0.848)	-0.027 (0.731)	0.107 (0.162)	0.238 (0.002)
SBP	0.051 (0.538)	0.006 (0.940)	0.041 (0.596)	0.109 (0.155)
DBP	-0.029 (0.729)	0.034 (0.674)	-0.042 (0.581)	0.058 (0.452)
FINS	-0.053 (0.523)	0.030 (0.707)	0.088 (0.250)	0.132 (0.084)
HbA1c	-0.114 (0.168)	-0.037 (0.639)	0.023 (0.765)	0.110 (0.153)
FPG	0.072 (0.387)	0.012 (0.877)	-0.074 (0.336)	0.032 (0.680)
ALT	-0.105 (0.204)	0.041 (0.607)	0.100 (0.191)	0.142 (0.062)
AST	-0.099 (0.231)	0.069 (0.384)	0.115 (0.133)	0.099 (0.194)
GGT	-0.095 (0.251)	0.057 (0.473)	0.088 (0.251)	0.123 (0.107)
Scr	0.075 (0.363)	0.077 (0.335)	0.219 (0.004)	0.049 (0.521)
UA	-0.067 (0.420)	0.035 (0.662)	0.171 (0.025)	0.139 (0.069)
TC	0.026 (0.755)	-0.053 (0.508)	-0.015 (0.849)	-0.116 (0.130)
TAG	-0.112 (0.177)	-0.113 (0.154)	0.002 (0.975)	-0.003 (0.973)
HDL-Ch	-0.014 (0.863)	0.063 (0.425)	0.014 (0.855)	-0.045 (0.556)
LDL-Ch	0.042 (0.616)	-0.083 (0.293)	-0.005 (0.950)	-0.098 (0.202)

超重肥胖青少年认知功能的改变及其与血清FGF21水平的关系

Alteration of cognitive function in overweight and obese adolescents and its relationship with serum FGF21 levels

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 8

参考文献 28

相关文章 15

编辑推荐

Metrics

Variable	β	STD	t value	P value
Flanker task
Incongruent stimulus
BMI	11.064	0.511	4.053	0.000
Hip circumference	-3.664	-0.315	-2.499	0.013
Congruent stimulus
BMI	6.468	0.295	4.043	0.000
n-back task
1-back
BMI	9.505	0.250	3.378	0.001
2-back
BMI	15.045	0.317	4.368	0.000

Variable	β	STD	t value	P value	adjusted R²
2-back ACC	-2.090	-0.334	-3.687	0.000	0.110
Reaction time for incongruent stimulus	0.002	0.182	2.004	0.048	0.110

[1]	高雄, 张秋霞, 杨苗苗, 罗玮, 王月刚, 修建成. 房颤与认知障碍的因果关系：一项孟德尔随机化研究[J]. 上海交通大学学报（医学版）, 2023, 43(11): 1359-1365.
[2]	张蓉, 陆丽, 王亚昕, 董文倩, 张宇, 周健. 糖尿病患者血糖波动异常与认知功能障碍关系的研究进展[J]. 上海交通大学学报(医学版), 2022, 42(2): 235-240.
[3]	陆如平, 高慧, 蒋琳娜, 陈晓亚, 彭红, 沈辉, 范青. 精神运动康复对稳定期精神分裂症患者阴性症状及认知功能的影响[J]. 上海交通大学学报(医学版), 2022, 42(1): 77-81.
[4]	王毅, 程诚, 沈红艳, 高红艳, 戴悦宁, 易正辉. 经颅磁刺激对阿尔茨海默病患者认知功能及伴痴呆的行为精神症状疗效的meta分析[J]. 上海交通大学学报(医学版), 2021, 41(7): 931-941.
[5]	胡国芹, 杨程青, 吕钦谕, 赵静, 朱明环, 易正辉, 戴兴海. 计算机化认知矫正治疗对精神分裂症患者认知功能的影响[J]. 上海交通大学学报(医学版), 2021, 41(5): 622-627.
[6]	黄文俊, 蒋素素, 陶敏芳. 围绝经期和绝经后女性睡眠质量与日常认知功能的相关性[J]. 上海交通大学学报(医学版), 2021, 41(4): 497-501.
[7]	夏安琪, 李军, 岳玲, 洪波, 严峰, 苏宁, 肖世富, 刘园园, 王涛. 蒙特利尔认知评估量表在中国社区老人中的应用[J]. 上海交通大学学报(医学版), 2021, 41(12): 1662-1667.
[8]	何海宁，张微，严峰，史琰琛，王静华，肖世富#，王涛#. 阿尔茨海默病引起的轻度认知功能损害的微小RNA表达谱的生物信息学分析[J]. 上海交通大学学报(医学版), 2020, 40(9): 1174-1183.
[9]	周绍宇1，冯振晓1，姚晓萍2，王万1，赵静3#，易正辉4#. 典型与非典型抗精神病药对精神分裂症患者认知症状的影响[J]. 上海交通大学学报(医学版), 2020, 40(8): 1075-1080.
[10]	罗钢，崔永晨，曹越，张俊峰. 手术创伤对2型糖尿病小鼠术后认知功能和脑葡萄糖代谢的影响[J]. 上海交通大学学报(医学版), 2020, 40(11): 1468-1472.
[11]	洪波，何海宁，刘园园，苏宁，严峰，史琰琛，王静华，王涛，肖世富. 认知功能正常老人睡眠与认知功能变化1年随访研究[J]. 上海交通大学学报（医学版）, 2019, 39(9): 1017-.
[12]	贾芷莹 1, 2，董旻晔 1, 2，施贞夙 2, 3，金春林 4，李国红 1, 2. 基于机器学习的轻度认知功能障碍筛查研究[J]. 上海交通大学学报（医学版）, 2019, 39(8): 908-.
[13]	王丹丹，张晨. 精神分裂症患者认知功能的神经免疫机制及非典型抗精神病药物对其影响的研究进展[J]. 上海交通大学学报（医学版）, 2019, 39(7): 795-.
[14]	朱丽娜 1，张琼 2，蔡军 1，张伟波 1，朱红霞 1. 小脑蚓部的 θ短阵快速脉冲模式重复经颅磁刺激对精神分裂症患者认知功能的影响[J]. 上海交通大学学报（医学版）, 2019, 39(3): 282-.
[15]	姜彩霞 1，邹敏 2，姜丽萍 2. 基于聚类分析的上海市 590位老人老年综合征的特征分析[J]. 上海交通大学学报（医学版）, 2018, 38(9): 1072-.

Item	ACC			Reaction time
Item	0-back	1-back	2-back	0-back	1-back	2-back
BMI	0.032 (0.701)	0.078 (0.344)	0.087 (0.299)	0.151 (0.069)	0.268 (0.000)	0.351 (0.000)
Body fat mass	0.027 (0.745)	0.057 (0.489)	0.061 (0.465)	0.124 (0.135)	0.217 (0.004)	0.282 (0.000)
Body fat percentage	0.030 (0.722)	0.042 (0.615)	0.062 (0.459)	0.065 (0.438)	0.173 (0.023)	0.240 (0.000)
Waist-to-hip ratio	0.002 (0.983)	-0.022 (0.794)	0.077 (0.357)	0.095 (0.253)	0.257 (0.000)	0.320 (0.000)
Waist circumference	-0.058 (0.491)	0.001 (0.986)	0.008 (0.921)	0.122 (0.143)	0.200 (0.008)	0.248 (0.000)
Hip circumference	-0.040 (0.635)	0.062 (0.454)	0.044 (0.602)	0.082 (0.328)	0.208 (0.006)	0.257 (0.000)
SBP	-0.051 (0.544)	0.012 (0.887)	0.101 (0.227)	-0.004 (0.961)	0.107 (0.164)	0.101 (0.186)
DBP	-0.099 (0.238)	-0.079 (0.344)	-0.056 (0.500)	0.059 (0.482)	0.137 (0.074)	0.059 (0.443)
FINS	-0.042 (0.612)	-0.085 (0.303)	-0.080 (0.339)	0.013 (0.872)	0.116 (0.128)	0.138 (0.070)
HbA1c	-0.028 (0.738)	-0.149 (0.071)	-0.085 (0.308)	0.001 (0.988)	0.103 (0.177)	0.055 (0.473)
FPG	-0.176 (0.035)	-0.114 (0.169)	-0.036 (0.666)	-0.139 (0.095)	-0.021 (0.790)	0.025 (0.741)
ALT	-0.067 (0.420)	-0.046 (0.580)	-0.067 (0.425)	0.046 (0.579)	0.161 (0.035)	0.207 (0.006)
AST	-0.008 (0.923)	-0.042 (0.614)	-0.060 (0.469)	0.045 (0.591)	0.156 (0.040)	0.199 (0.009)
GGT	0.061 (0.464)	-0.068 (0.413)	-0.148 (0.075)	0.017 (0.835)	0.161 (0.034)	0.139 (0.068)
Scr	-0.050 (0.546)	-0.173 (0.035)	-0.021 (0.798)	0.032 (0.700)	0.085 (0.264)	0.101 (0.188)
UA	0.032 (0.698)	-0.093 (0.260)	-0.140 (0.093)	0.158 (0.057)	0.227 (0.003)	0.310 (0.000)
TC	0.182 (0.028)	-0.016 (0.850)	-0.059 (0.483)	-0.037 (0.656)	0.029 (0.709)	-0.028 (0.719)
TAG	0.051 (0.539)	-0.092 (0.267)	-0.223 (0.007)	0.058 (0.488)	0.027 (0.722)	0.026 (0.732)
HDL-Ch	0.075 (0.366)	0.011 (0.893)	0.098 (0.240)	0.042 (0.619)	-0.024 (0.752)	-0.116 (0.127)
LDL-Ch	0.158 (0.058)	-0.010 (0.907)	-0.076 (0.364)	-0.058 (0.484)	0.068 (0.371)	0.036 (0.638)

Item	ACC			Reaction time
Item	0-back	1-back	2-back	0-back	1-back	2-back
BMI	0.032 (0.701)	0.078 (0.344)	0.087 (0.299)	0.151 (0.069)	0.268 (0.000)	0.351 (0.000)
Body fat mass	0.027 (0.745)	0.057 (0.489)	0.061 (0.465)	0.124 (0.135)	0.217 (0.004)	0.282 (0.000)
Body fat percentage	0.030 (0.722)	0.042 (0.615)	0.062 (0.459)	0.065 (0.438)	0.173 (0.023)	0.240 (0.000)
Waist-to-hip ratio	0.002 (0.983)	-0.022 (0.794)	0.077 (0.357)	0.095 (0.253)	0.257 (0.000)	0.320 (0.000)
Waist circumference	-0.058 (0.491)	0.001 (0.986)	0.008 (0.921)	0.122 (0.143)	0.200 (0.008)	0.248 (0.000)
Hip circumference	-0.040 (0.635)	0.062 (0.454)	0.044 (0.602)	0.082 (0.328)	0.208 (0.006)	0.257 (0.000)
SBP	-0.051 (0.544)	0.012 (0.887)	0.101 (0.227)	-0.004 (0.961)	0.107 (0.164)	0.101 (0.186)
DBP	-0.099 (0.238)	-0.079 (0.344)	-0.056 (0.500)	0.059 (0.482)	0.137 (0.074)	0.059 (0.443)
FINS	-0.042 (0.612)	-0.085 (0.303)	-0.080 (0.339)	0.013 (0.872)	0.116 (0.128)	0.138 (0.070)
HbA1c	-0.028 (0.738)	-0.149 (0.071)	-0.085 (0.308)	0.001 (0.988)	0.103 (0.177)	0.055 (0.473)
FPG	-0.176 (0.035)	-0.114 (0.169)	-0.036 (0.666)	-0.139 (0.095)	-0.021 (0.790)	0.025 (0.741)
ALT	-0.067 (0.420)	-0.046 (0.580)	-0.067 (0.425)	0.046 (0.579)	0.161 (0.035)	0.207 (0.006)
AST	-0.008 (0.923)	-0.042 (0.614)	-0.060 (0.469)	0.045 (0.591)	0.156 (0.040)	0.199 (0.009)
GGT	0.061 (0.464)	-0.068 (0.413)	-0.148 (0.075)	0.017 (0.835)	0.161 (0.034)	0.139 (0.068)
Scr	-0.050 (0.546)	-0.173 (0.035)	-0.021 (0.798)	0.032 (0.700)	0.085 (0.264)	0.101 (0.188)
UA	0.032 (0.698)	-0.093 (0.260)	-0.140 (0.093)	0.158 (0.057)	0.227 (0.003)	0.310 (0.000)
TC	0.182 (0.028)	-0.016 (0.850)	-0.059 (0.483)	-0.037 (0.656)	0.029 (0.709)	-0.028 (0.719)
TAG	0.051 (0.539)	-0.092 (0.267)	-0.223 (0.007)	0.058 (0.488)	0.027 (0.722)	0.026 (0.732)
HDL-Ch	0.075 (0.366)	0.011 (0.893)	0.098 (0.240)	0.042 (0.619)	-0.024 (0.752)	-0.116 (0.127)
LDL-Ch	0.158 (0.058)	-0.010 (0.907)	-0.076 (0.364)	-0.058 (0.484)	0.068 (0.371)	0.036 (0.638)